Pack size: Strip of 10 Tablets  |  Price is for the whole Strip

⚠ Prescription required. This medicine may only be dispensed against a valid prescription.

Generic: Vonoprazan

Form: Tablet 20mg

Indications

Vonoprazan is indicated for: Gastric ulcer, duodenal ulcer, reflux esophagitis, prevention of recurrence of gastric or duodenal ulcer during low-dose aspirin administration, prevention of recurrence of gastric or duodenal ulcer during NSAID administration. Adjunct to Helicobacter pylori eradication in the following: Gastric ulcer, duodenal ulcer, gastric mucosa-associated lymphatic tissue (MALT) lymphoma, idiopathic thrombocytopenic purpura, the stomach after endoscopic resection of early-stage gastric cancer or Helicobacter pylori gastritis.

Pharmacology

Vonoprazan is a potassium competitive acid blocker (P-CAB) and does not require activation by acid. It inhibits H+, K+-ATPase in a reversible and potassium-competitive manner. Vonoprazan has a strong basicity and resides on the acid production site of gastric parietal cells for a long time, thereby inhibiting gastric acid production. Vonoprazan exerts a strong inhibitory effect on formation of mucosal damage in upper part of the gastrointestinal tract.

Dosage

$4b

Administration

Vonoprazan can be taken without regard to food or timing of food. Use in the elderly: Since the physiological functions such as hepatic or renal function are decreased in elderly patients in general,Vonoprazan should be carefully administered. Use in children less than 18 years of age: The safety and efficacy of Vonoprazan in children and adolescence have not been established. Therefore, the administration of Vonoprazan is not recommended in children and adolescents below 18 years of age. * Take medicine as per doctor's advice.

Contraindications

Vonoprazan is contraindicated in: Patients with hypersensitivity to Vonoprazan or to any excipient of the product. Patients receiving atazanavir sulphate, nelfinavir or rilpivirine hydrochloride.

Side Effects

Following side effects have been reported with the use of Vonoprazan: Diarrhea, constipation, drug hypersensitivity (including anaphylactic shock), drug eruption, urticaria, hepatotoxicity, jaundice, rash, nausea, abdominal distension, gamma-glutamyl transferase increased, AST increased, Liver function test abnormal, ALT increased, ALP increased, LDH increased, y-GPT increased, edema and eosinophilia

Precautions & Warnings

At the treatment, the course of the disease should closely be observed and the minimum therapeutic necessity should be used according to the disease condition. In the long-term, treatment with Vonoprazan, close observation by such means as endoscopy should be made. In the maintenance of healing of reflux esophagitis, Vonoprazan should be administered only to the patients who repeat recurrence and recrudescence of the condition. Administration to the patients who do not necessitate maintenance of healing should be avoided. When the healing is maintained over a long period and when there is no risk of recurrence, the dose reduction to a dose of 10mg from a dose 20mg, or suspension of administration should be considered.

Overdose Effects

There is no experience of overdose with Vonoprazan . Vonoprazan is not removed from the circulation by hemodialysis. If overdose occurs, treatment should be symptomatic and supportive.

Safety Advice

Caution is advised when consuming alcohol with Vonoprazan.

Safety Advice

Vonoprazan should be used in pregnant women or women having possibility of being pregnant only if the expected therapeutic benefit is thought to outweigh any possible risk.

Safety Advice

It is advisable to avoid the administration of Vonoprazan to nursing mothers. However, when the administration is indispensable, nursing should be discontinued.

Safety Advice

Do not drive if you experience any symptoms that affect your ability to concentrate and react. It is not clearly known whether Vonoprazan alters the ability to drive.

Safety Advice

Patients with renal impairment: No dose adjustment of Vonoprazan is recommended in patients with mild to moderate renal impairment (eGFR 30 to 89 mL/min). Avoid the use of Vonoprazan in patients with severe renal impairment (eGFR < 30 mL/min).

Safety Advice

Patients with hepatic impairment: No dose adjustment of Vonoprazan is recommended in patients with mild hepatic impairment (Child-Pugh A). Avoid the use of Vonoprazan in patients with moderate to severe hepatic impairment (Child-Pugh B or C).